Zenith Health (530665)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Piotroski F-Score of 7/9 indicates recent improvement in financial health and operating efficiency.
• Sales grew 7.36%, providing a modest but positive top-line base.
• Reported profit growth of 175.86% and a PEG of 0.43 could signal early earnings recovery if the base stabilises.
• Latest quarterly sales of ₹2 Cr show the business is operational, not dormant.

Concerns

• P/E of 39.40 and P/B of 3.40 are expensive for ROE of 6.02% and ROCE of 3.12%.
• Latest quarter net profit of ₹0 Cr suggests the profit surge may be a rounding artifact or unsustainable base effect.
• No dividend, no promoter holding disclosure, and N/A debt/equity create serious transparency and leverage risks.
• Tiny scale with quarterly sales of ₹2 Cr and only 7.36% sales growth makes the business vulnerable to competitive and regulatory shocks.

AI Analysis

At ₹5.20, Zenith Health is a tiny pharmaceutical business with a market capitalisation of just ₹28 crore. Graham would tell me to start with the balance sheet and the earnings record, and neither gives me much comfort. The stock trades at 39.4 times earnings and 3.4 times book value, while the company earns only 6.02% return on equity and 3.12% on capital employed. Those returns are far below what I expect from a business with a durable moat. A pharmaceutical company should be generating excess returns on its research and brands; this one is barely covering its cost of capital. The 175.86% profit growth and PEG ratio of 0.43 look tempting, but I must ask: growth from what base? The latest quarter shows sales of ₹2 crore and net profit of roughly ₹0 crore. A single rupee of rounding can make a huge percentage swing. With sales growth of just 7.36%, this is not a fast-growing franchise. The Piotroski F-Score of 7/9 is the only encouraging sign; it suggests working capital and asset quality may be improving. But F-scores measure recent financial mechanics, not competitive strength. I also notice there is no dividend, no promoter holding data, and no debt-to-equity figure. In a ₹28 crore micro-cap, undisclosed ownership and ambiguous leverage are serious red flags. I cannot calculate a reliable margin of safety when critical information is missing. At the 52-week high of ₹5.20, the market is already optimistically pricing in continued improvement. As Buffett says, it is far better to buy a wonderful company at a fair price than a fair company at a wonderful price. This is a small, low-return, financially opaque business at a rich valuation. I will watch it from the sidelines.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer